We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

182 hedge funds and large institutions have $1.44B invested in ChemoCentryx, Inc. in 2022 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 72 increasing their positions, 52 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

292% more call options, than puts

Call options by funds: $40.3M | Put options by funds: $10.3M

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

38% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 52

30% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 30

3% more funds holding

Funds holding: 176182 (+6)

3% more capital invested

Capital invested by funds: $1.4B → $1.44B (+$40.7M)

Holders
182
Holders Change
+6
Holders Change %
+3.41%
% of All Funds
3.07%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
39
Increased
72
Reduced
52
Closed
30
Calls
$40.3M
Puts
$10.3M
Net Calls
+$30M
Net Calls Change
+$12.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$265M +$1.08M +48,951 +0.5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$144M +$15.1M +686,912 +13%
BlackRock
3
BlackRock
New York
$115M +$7.57M +343,317 +8%
State Street
4
State Street
Massachusetts
$100M +$8.91M +404,301 +11%
PAMS
5
Pictet Asset Management (Switzerland)
Switzerland
$58.8M +$11.7M +532,478 +29%
WA
6
Wasatch Advisors
Utah
$52.1M +$22.6M +1,027,231 +95%
BBA
7
Baker Bros. Advisors
New York
$44.4M +$19.3M +875,795 +96%
Invesco
8
Invesco
Georgia
$42.7M +$2.43M +110,203 +7%
GKIM
9
GW&K Investment Management
Massachusetts
$38.1M +$8.28M +375,530 +32%
CAM
10
Cormorant Asset Management
Massachusetts
$35.3M +$12.3M +560,000 +65%
HRCM
11
Hood River Capital Management
Florida
$33.1M +$29.5M +1,336,776 New
Marshall Wace
12
Marshall Wace
United Kingdom
$29.2M -$4.84M -219,635 -16%
HM
13
HealthCor Management
New York
$27.2M +$3.1M +140,630 +15%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$25M +$144K +6,519 +0.7%
Morgan Stanley
15
Morgan Stanley
New York
$22.5M +$10.7M +484,877 +115%
N
16
Nuveen
North Carolina
$22.1M +$7.34M +332,802 +60%
EAM
17
Eventide Asset Management
Massachusetts
$18M
Northern Trust
18
Northern Trust
Illinois
$15.9M +$1.91M +86,824 +16%
SI
19
Sofinnova Investments
California
$15.8M +$1.39M +62,975 +11%
LGM
20
Logos Global Management
California
$14.9M +$13.2M +600,000 New
Wellington Management Group
21
Wellington Management Group
Massachusetts
$14.4M -$1.43M -64,783 -10%
IHAM
22
Integral Health Asset Management
New York
$14.2M +$3.84M +174,029 +44%
Principal Financial Group
23
Principal Financial Group
Iowa
$13.7M +$5.5M +249,434 +82%
Norges Bank
24
Norges Bank
Norway
$13.6M -$13M -590,836 -52%
Barclays
25
Barclays
United Kingdom
$13.6M +$11.1M +505,000 +1,199%

CCXI Hedge Fund Activity: Q2 2022 in Review

182 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q2 2022, worth a combined $1.44B — up 2.9% from $1.4B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CCXI positions and 30 closed out — a net gain of 9 holders — while 72 added to existing stakes and 52 trimmed.

The largest buyer was Hood River Capital Management, opening a new position worth an estimated $29.5M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.5M sold.

  • 182 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q2 2022, up from 176 in Q1 2022.
  • Funds reported $1.44B of ChemoCentryx, Inc. stock for Q2 2022, up 2.9% quarter-over-quarter.
  • 39 funds opened new ChemoCentryx, Inc. positions in Q2 2022 and 30 closed out, a net change of +9 holders.
  • The largest ChemoCentryx, Inc. buyer in Q2 2022 was Hood River Capital Management, an estimated $29.5M added.
  • The largest ChemoCentryx, Inc. seller in Q2 2022 was Avidity Partners Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q2 2022.